Printer Friendly
The Free Library
14,582,462 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Sepracor Inc. Sets Conference Call and Webcast for Third Quarter 2005 Operating Results.


MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR SEPR Senior Enlisted Performance Report ) will announce its third quarter 2005 financial results on October 25, 2005. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on October 25, 2005 to discuss its third quarter 2005 financial results.

To participate via telephone, dial 973-582-2749 and refer to conference identification number 6579246. Please call ten minutes prior to the scheduled conference call time.

For live webcasting, go to the Sepracor web site at www.sepracor.com and access the For Investors section. Click on either the live webcast link or microphone icon to listen. Please go to the web site at least 15 minutes prior to the call in order to register, download To receive a file transmitted over a network. In any communications session, "download" means receive, and "upload" means send. The download/upload often implies a big/little scenario, in which data is being downloaded from the "big" server into the "little" user's computer. , and install any necessary software.

A .pdf file See PDF.  of the slides will also be made available in the For Investors section of the web site just prior to the commencement of the webcast.

A replay of the call will be accessible by telephone after 10:30 a.m. ET and will be available for approximately one week. To replay the call, dial 973-341-3080 using access code 6579246.

Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development and commercialization of innovative pharmaceutical products that are directed toward serving unmet un·met  
adj.
Not satisfied or fulfilled: unmet demands. 
 medical needs. Sepracor's drug development program has yielded an extensive portfolio of pharmaceutical compound candidates with a focus on respiratory and central nervous system disorders Nervous system disorders

A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency
. The company's commercialization efforts are carried out by its U.S.-based, 1,250-person, primary care and specialty-oriented sales force. Sepracor's corporate headquarters are located in Marlborough, Massachusetts Marlborough is a city in Middlesex County, Massachusetts, United States. The population was 36,255 at the 2000 census. The name of this town is sometimes spelled as Marlboro, rather than Marlborough, which is the official spelling. .

For a copy of this release or any recent release, visit www.sepracor.com.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Oct 11, 2005
Words:290
Previous Article:Fitness Experts Launch Exercise Franchise for Men Only; Nitro Fitness Offers the Average Guy a 30-Minute Workout.
Next Article:Momentum for Software-as-Service Solutions is Particularly Strong in Three Vertical Industries: Construction, Healthcare and Financial Services, Says...
Topics:



Related Articles
Sepracor Inc. Sets Conference Call and Webcast for Second Quarter 2005 Operating Results.
IVAX Reports 3rd Quarter 2005 Results; Revenues up 41% to Record $617.7 Million; Net Income up 25% to $55.4 Million; EPS up 18% to $0.20.
Sepracor Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2005 Operating Results.
Sepracor Inc. Sets Conference Call and Webcast for First Quarter 2006 Operating Results.
ACADIA Pharmaceuticals Reports Second Quarter 2006 Financial Results.
ACADIA Pharmaceuticals Reports Third Quarter 2006 Financial Results.
ImClone Systems Reports Third Quarter and Nine Months 2006 Financial Results.
Sepracor Inc. Sets Conference Call and Webcast for Third Quarter 2006 Operating Results.
Sepracor Announces Fourth Quarter and Full Year 2006 Results.(Financial report)
Sepracor Announces First Quarter 2007 Results.(Financial report)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles